- Home
- MIRM vs WFRD Comparison
MIRM vs WFRD Comparison
Compare MIRM & WFRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | WFRD |
|---|---|---|
| Founded | 2018 | 1941 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.5B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MIRM | WFRD |
|---|---|---|
| Price | $91.20 | $84.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $119.85 | $103.22 |
| AVG Volume (30 Days) | 464.4K | ★ 888.2K |
| Earning Date | 05-06-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.03% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ 2.04 |
| Revenue | $19,138,000.00 | ★ $4,331,000,000.00 |
| Revenue This Year | $26.22 | N/A |
| Revenue Next Year | $22.04 | $5.22 |
| P/E Ratio | ★ N/A | $40.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $63.23 | $60.84 |
| 52 Week High | $130.00 | $113.15 |
Technical Indicators
Market Signals| Indicator | MIRM | WFRD |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 35.92 |
| Support Level | $88.08 | $77.56 |
| Resistance Level | $98.03 | $85.67 |
| Average True Range (ATR) | 3.90 | 3.34 |
| MACD | -0.37 | -1.26 |
| Stochastic Oscillator | 10.13 | 14.94 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About WFRD Weatherford International plc
Weatherford provides oilfield services and equipment to national, integrated, public, and private oil and gas operators. It operates across multiple upstream markets, including offshore, the rest of the world onshore, and US onshore, where Weatherford has limited exposure. The Middle East, North Africa, and Asia account for over 25% of sales. Weatherford also offers manufacturing, research, and training services. Performance is reported through three segments: drilling and evaluation, well construction and completions, and production and intervention.